CAREMAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.99 USD | -0.66% |
|
-9.67% | -79.99% |
| 05-09 | Earnings Flash (CMAX) CAREMAX Reports Q1 Revenue $232.2M | MT |
| 04-01 | UBS Trims CareMax Price Target to $6.40 From $7, Maintains Neutral Rating | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2026.
- The company shows low valuation levels, with an enterprise value at 0.51 times its sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -79.99% | 11.37M | - | ||
| +20.68% | 85.55B | C+ | ||
| -29.31% | 70.07B | B- | ||
| +9.65% | 29.06B | C+ | ||
| -8.63% | 17.51B | B | ||
| +2.14% | 17.39B | A- | ||
| +0.39% | 15.38B | A- | ||
| +6.47% | 13.4B | B- | ||
| +68.09% | 12.87B | C- | ||
| +6.43% | 12.77B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CMAX Stock
- Ratings CareMax, Inc.
